Number 773 • December 2018

# Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Jamp-Zolmitriptan ODT 2.5 mg Orally Dispersible Tablet (DIN 02428237) manufactured by Jamp Pharma Corporation, Septa-Zolmitriptan ODT 2.5 mg Orally Dispersible Tablet (DIN 02428474) manufactured by Septa Pharmaceuticals Inc., Van-Zolmitriptan ODT 2.5 mg Orally Dispersible Tablet (DIN 02438763) manufactured by Vanc Pharmaceuticals Inc, and Zomig Rapimelt 2.5 mg Orally Dispersible Tablet (DIN 02243045) manufactured by Astrazeneca Canada Inc., Sandoz Zolmitriptan ODT 2.5 mg Orally Dispersible Tablet (DIN 02362996) manufactured by Sandoz Canada Inc. will be considered a temporary benefit for the Alberta Drug Benefit List (ADBL).

As of **December 3, 2018**, all claims for Sandoz Zolmitriptan ODT 2.5 mg Orally Dispersible Tablet (DIN 02362996) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **www.ab.bluecross.ca/providers/pharmacy-home.html**.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the ADBL in order to remain as a benefit.

# Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Methylphenidate 10 mg Tablet (DIN 02249324) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 3, 2019**.

#### **METHYLPHENIDATE HCL**

## 10 MG TABLET

00002249324	APO-METHYLPHENIDATE	APX	\$ 0.0816
00000584991	PMS-METHYLPHENIDATE	PMS	\$ 0.0816
0000005606	RITALIN	NOV	\$ 0.3786

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Quinapril/HCTZ 20 mg/25 mg Tablet (DIN 02408783) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 3, 2019**.

#### QUINAPRIL/ HYDROCHLOROTHIAZIDE

## **20 MG / 25 MG TABLET**

00002408783	APO-QUINAPRIL/HCTZ	APX	\$ 0.6512
00002237369	ACCURETIC 20/25	PFI	\$ 0.9203

## Removal of temporary benefit from the Alberta Drug Benefit List (ADBL)

Due to the shortage of pms-Sulfasalazine 500 mg Tablet (DIN 00598461) manufactured by Pharmascience Inc., Salazopyrin 500 mg Tablet (DIN 02064480) manufactured by Pfizer Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Pharmascience Inc. has advised Alberta Blue Cross that the shortage of pms-Sulfasalazine 500 mg Tablet (DIN 00598461) has been resolved.

As a result, pms-Sulfasalazine 500 mg Tablet (DIN 00598461) will no longer be considered a temporary benefit for the *ADBL* after **January 3, 2018**.

## When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit ab.bluecross.ca/providers/pharmacy-home.php** 



